Analyst Reco. PAVmed Inc.

Equities

PAVM

US70387R4039

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
1.72 ^USD	-2.82%		-7.53%	-58.25%

03-27	Transcript : PAVmed Inc., Q4 2023 Earnings Call, Mar 27, 2024
03-25	PAVmed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantor Fitzgerald Downgrades PAVmed to Neutral From Overweight, Cuts Price Target to $1.50 From $4	20/01/23	MT
Lake Street Adjusts PAVmed's Price Target to $1.50 From $5, Maintains Buy Rating	18/01/23	MT
Lake Street Trims Price Target on PAVmed to $5 From $7, Reiterates Buy Rating	17/08/22	MT
Cantor Fitzgerald Adjusts PAVmed's Price Target to $5 from $6, Keeps Overweight Rating	30/03/22	MT
PAVMED : Cantor Fitzgerald Starts PAVmed at Overweight With $8 Price Target	30/03/21	MT
PAVMED : Ascendiant Capital Starts PAVmed at Buy With $5 Price Target	05/11/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer